Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Baxter
Merck
Dow
McKinsey

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Ganaxolone

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Ganaxolone: Patents, clinical trial progress, indications

Ganaxolone is an investigational drug.

There have been 16 clinical trials for Ganaxolone. The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2013.

The most common disease conditions in clinical trials are Epilepsy, Disease, and Seizures. The leading clinical trial sponsors are Marinus Pharmaceuticals, U.S. Army Medical Research and Materiel Command, and INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium.

There are ninety-five US patents protecting this investigational drug and eight hundred and ninety-five international patents.

Recent Clinical Trials for Ganaxolone
TitleSponsorPhase
Study of Adjunctive Ganaxolone Treatment in Female Children With Protocadherin 19 (PCDH19)-Related Epilepsy (Violet Study)Marinus PharmaceuticalsPhase 3
Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency DisorderMarinus PharmaceuticalsPhase 3
A Clinical Trial of Oral Ganaxolone in Women With Postpartum DepressionMarinus PharmaceuticalsPhase 2

See all Ganaxolone clinical trials

Clinical Trial Summary for Ganaxolone

Top disease conditions for Ganaxolone
Top clinical trial sponsors for Ganaxolone

See all Ganaxolone clinical trials

US Patents for Ganaxolone

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ganaxolone   Start Trial Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties RESEARCH TRIANGLE INSTITUTE (Research Triangle Park, NC) THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (Washington, DC)   Start Trial
Ganaxolone   Start Trial Uses of ganaxolone WISCONSIN ALUMNI RESEARCH FOUNDATION (Madison, WI)   Start Trial
Ganaxolone   Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Start Trial
Ganaxolone   Start Trial Sugar ester nanoparticle stabilizers St. John's University (Queens, NY)   Start Trial
Ganaxolone   Start Trial Method of treating organophosphate intoxication by administration of neurosteroids The Texas A&M University System (College Station, TX)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ganaxolone

Drugname Country Document Number Estimated Expiration Related US Patent
Ganaxolone Australia 2008265898 2027-06-15   Start Trial
Ganaxolone Canada 2698172 2027-06-15   Start Trial
Ganaxolone European Patent Office 2155204 2027-06-15   Start Trial
Ganaxolone Spain 2589139 2027-06-15   Start Trial
Ganaxolone Japan 2010530004 2027-06-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Merck
Baxter
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.